Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM78NWP)

• Drug Name: Dostarlimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Approved	[1]
Neoplasm	2A00-2F9Z	Phase 3	[2]
Breast cancer	2C60-2C65	Phase 2	[3]
Multiple myeloma	2A83	Phase 2	[4]

• Cross-matching ID: TTD Drug ID: DM78NWP

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[6]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[7]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[6]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[8]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[9]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[10]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[11]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[12]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[13]
BGB-A317	DM7NJYC	Hepatocellular carcinoma	2C12.02	Phase 3	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[5]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [2] ClinicalTrials.gov (NCT03981796) A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
• [5] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [8] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [12] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)